Neximmune Financial Statements From 2010 to 2026
| NEXI Stock | USD 0.0001 0.0001 50.00% |
Check Neximmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neximmune's main balance sheet or income statement drivers, such as , as well as many indicators such as . Neximmune financial statements analysis is a perfect complement when working with Neximmune Valuation or Volatility modules.
Neximmune |
Neximmune Company Return On Equity Analysis
Neximmune's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neximmune Return On Equity | -1.96 |
Most of Neximmune's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Neximmune has a Return On Equity of -1.9648. This is 91.8% lower than that of the Biotechnology sector and 94.61% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Neximmune Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neximmune's current stock value. Our valuation model uses many indicators to compare Neximmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neximmune competition to find correlations between indicators driving Neximmune's intrinsic value. More Info.Neximmune is considered to be number one stock in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neximmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neximmune's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Neximmune Financial Statements
Investors use fundamental indicators, such as Neximmune's revenue or net income, to determine how well the company is positioned to perform in the future. Although Neximmune's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Neximmune Pink Sheet
Neximmune financial ratios help investors to determine whether Neximmune Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neximmune with respect to the benefits of owning Neximmune security.